NO20092455L - Modulering av prostaglandin/syklooksygenase-metabolske baner - Google Patents

Modulering av prostaglandin/syklooksygenase-metabolske baner

Info

Publication number
NO20092455L
NO20092455L NO20092455A NO20092455A NO20092455L NO 20092455 L NO20092455 L NO 20092455L NO 20092455 A NO20092455 A NO 20092455A NO 20092455 A NO20092455 A NO 20092455A NO 20092455 L NO20092455 L NO 20092455L
Authority
NO
Norway
Prior art keywords
metabolic pathways
cyclooxygenase
prostaglandin
modulation
inflammation
Prior art date
Application number
NO20092455A
Other languages
English (en)
Inventor
Ernst Wulfert
Original Assignee
Hunter Fleming Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0623971A external-priority patent/GB0623971D0/en
Application filed by Hunter Fleming Ltd filed Critical Hunter Fleming Ltd
Publication of NO20092455L publication Critical patent/NO20092455L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Otolaryngology (AREA)

Abstract

En rekke forskjellige sykdommer og forstyrrelser som er forbundet med de metabolske reaksjonsveiene som inngår i aktiviteten av syklooksygenase og syntesen av prostaglandiner, f.eks. type 2 diabetes mellitus og følgene av denne, iskemiske karsykdommer, smerte forbundet med betennelse, betennelsestilstander i huden, ryggmargsskade, perifer nevropati, multippel sklerose, inflammatorisk tarmsykdom og reumatoid artritt, så vel som forskjellige typer av kreft kan behandles eller forebygges ved anvendelse av et middel som selektivt fremmer dannelsen av 15deoksyprostaglandin J2.
NO20092455A 2006-11-30 2009-06-29 Modulering av prostaglandin/syklooksygenase-metabolske baner NO20092455L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US86787306P 2006-11-30 2006-11-30
GB0623971A GB0623971D0 (en) 2006-11-30 2006-11-30 Modulation of prostaglandin/cyclooxygenase metabolic pathways
PCT/GB2007/004584 WO2008065408A2 (en) 2006-11-30 2007-11-29 Modulation of prostaglandin/cyclooxygenase metabolic pathways

Publications (1)

Publication Number Publication Date
NO20092455L true NO20092455L (no) 2009-08-14

Family

ID=39381924

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20092455A NO20092455L (no) 2006-11-30 2009-06-29 Modulering av prostaglandin/syklooksygenase-metabolske baner

Country Status (14)

Country Link
US (2) US20100137270A1 (no)
EP (2) EP2147673A1 (no)
JP (1) JP2010511028A (no)
KR (1) KR20090086272A (no)
AU (1) AU2007327011A1 (no)
CA (1) CA2670957A1 (no)
HR (1) HRP20120687T1 (no)
IL (1) IL199013A0 (no)
MX (1) MX2009005753A (no)
NO (1) NO20092455L (no)
PL (1) PL2097079T3 (no)
TW (1) TWI414298B (no)
WO (1) WO2008065408A2 (no)
ZA (1) ZA200903584B (no)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2422828A (en) * 2005-02-03 2006-08-09 Hunter Fleming Ltd Tricyclic cytoprotective compounds comprising an indole residue
GB0523550D0 (en) 2005-11-18 2005-12-28 Hunter Fleming Ltd Therapeutic uses of steroidal compounds
WO2013120851A1 (en) * 2012-02-13 2013-08-22 Mach-3D Sàrl Method for sharing emotions through the creation of three-dimensional avatars and their interaction through a cloud-based platform
US9328060B2 (en) 2013-10-18 2016-05-03 East Carolina University J-series prostaglandin-ethanolamides as novel therapeutics
JP6917631B2 (ja) * 2016-02-15 2021-08-11 学校法人近畿大学 抗不安作用を有する医薬組成物および加工食品
WO2023060107A1 (en) * 2021-10-05 2023-04-13 University Of South Florida Compositions and uses thereof for treatment of neurological disorders

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7100213A (en) * 1971-01-08 1972-07-11 1,2,3,4-tetrahydrocarbazole derivs - anti-inflammatories
FR2696934B1 (fr) * 1992-10-20 1995-06-02 Conservatoire Nal Arts Metiers Dérivés de stéroïdes naturels 3B hydroxyles ayant des propriétés de déclenchement et de stimulation de l'immunité, composition les contenant et procédé pour les obtenir.
US5451600A (en) * 1994-04-19 1995-09-19 Hoffmann-La Roche Inc. Substituted tetrahydrobenzopyrrolylfuranoic acid derivatives as phospholipase A2 inhibitors
JP3258027B2 (ja) * 1996-03-15 2002-02-18 サマーセット・ファーマシューティカルズ・インコーポレイテッド セレジリン投与による末梢ニューロパシーの予防および治療方法
WO2000006560A1 (en) * 1998-07-30 2000-02-10 Warner-Lambert Company Tricyclic heteroaromatics and their derivatives as inhibitors of matrix metalloproteinases
US20030060425A1 (en) * 1998-11-24 2003-03-27 Ahlem Clarence N. Immune modulation method using steroid compounds
US20030083231A1 (en) * 1998-11-24 2003-05-01 Ahlem Clarence N. Blood cell deficiency treatment method
US6667299B1 (en) * 2000-03-16 2003-12-23 Hollis-Eden Pharmaceuticals, Inc. Pharmaceutical compositions and treatment methods
GB0003524D0 (en) * 2000-02-15 2000-04-05 Btg Int Ltd Cytoprotective steroids (II)
GB2363983A (en) 2000-06-29 2002-01-16 Hunter Fleming Ltd Protection against neuronal damage using 7-hydroxyepiandrosterone
GB2363984A (en) 2000-06-29 2002-01-16 Hunter Fleming Ltd Protection against neuronal damage using 3-hydroxy-7 -hydroxy steroids and 3-oxo-7 -hydroxy steroids
WO2002015791A2 (en) 2000-08-25 2002-02-28 Michael John Till Sampling device
EP2135611A1 (en) * 2001-03-01 2009-12-23 Hollis-Eden Pharmaceuticals Inc. Pregn-5-en-20-yne-3,7,17-triol derivatives for use in therapy
SE0100857D0 (sv) * 2001-03-13 2001-03-13 Tomas Hagstroem Treatment of tumors
GB2378898A (en) 2001-08-14 2003-02-26 Hunter Fleming Ltd Prophylactic and therapeutic use of hydroxysteroids
FR2829697B1 (fr) * 2001-09-14 2004-03-19 Mayoly Spindler Lab Derives 7-hydroxyles et 7-cetoniques des hormones steroides 3 beta-hydroxylees pour le traitement des maladies inflammatoires ou fonctionnelles de l'intestin
GB0403889D0 (en) * 2004-02-21 2004-03-24 Univ Edinburgh Uses of er-beta modulators
US20070231373A1 (en) * 2004-04-28 2007-10-04 Hunter-Fleming Limited Transdermal Steriod for Formulation
GB2422828A (en) * 2005-02-03 2006-08-09 Hunter Fleming Ltd Tricyclic cytoprotective compounds comprising an indole residue
US20060234993A1 (en) * 2005-04-13 2006-10-19 Eric Marchewitz Use of androstane derivatives for enhancing physical performance

Also Published As

Publication number Publication date
WO2008065408A9 (en) 2011-03-03
WO2008065408A2 (en) 2008-06-05
KR20090086272A (ko) 2009-08-11
MX2009005753A (es) 2009-09-28
WO2008065408A3 (en) 2008-11-20
US20130023504A1 (en) 2013-01-24
EP2097079A2 (en) 2009-09-09
ZA200903584B (en) 2010-11-24
TWI414298B (zh) 2013-11-11
CA2670957A1 (en) 2008-06-05
EP2097079B1 (en) 2012-06-27
EP2147673A1 (en) 2010-01-27
US20100137270A1 (en) 2010-06-03
IL199013A0 (en) 2010-02-17
JP2010511028A (ja) 2010-04-08
HRP20120687T1 (hr) 2012-09-30
TW200831108A (en) 2008-08-01
AU2007327011A1 (en) 2008-06-05
PL2097079T3 (pl) 2012-11-30

Similar Documents

Publication Publication Date Title
NO20092455L (no) Modulering av prostaglandin/syklooksygenase-metabolske baner
EA201000321A1 (ru) Фармацевтическая композиция, содержащая глюкопиранозилзамещенное производное бензола
EA200900177A1 (ru) Замещенные ациланилиды и способы их применения
WO2010049678A3 (en) Treatment of energy utilization diseases
MY149316A (en) Sirtuin modulating imidazohiazole compounds
ATE539748T1 (de) Glucokinaseaktivatoren
WO2007102861A3 (en) Modulators of cdc2-like kinases (clks) and methods of use thereof
EA201300522A1 (ru) Фармацевтические комбинации для лечения метаболических нарушений
EA200802204A1 (ru) Применение ингибиторов dpp iv
EA201101189A1 (ru) Ингибитор sglt-2, предназначенный для лечения сахарного диабета типа 1, сахарного диабета типа 2, нарушенной толерантности к глюкозе или гипергликемии
EA201300550A1 (ru) Фармацевтическая композиция, способы лечения и их применение
WO2008156869A3 (en) Sirtuin modulating thiazolopyridine compounds
DE602007008042D1 (de) Waschdesinfektor mit Bad, an das die Ablage mit daran befestigtem Endoskop abnehmbar geladen ist
EA201200975A1 (ru) Тиено[2,3-b]пиридиндионовые активаторы амфк и их терапевтическое применение
CL2004000639A1 (es) Compuestos derivados de quinolina y quinoxalina, composicion farmaceutica, combinacion farmaceutica; kit farmaceutico; y su uso para tratar aterosclerosis, enfermedad de arteria coronaria, enfermedad cardiaca coronaria, enfermedad vascular coronaria,
EP1742643A4 (en) MODULATION OF GLUCOSE-6-PHOSPHATASE TRANSLOKASE EXPRESSION
WO2009068659A3 (en) Novel disease treatment by predicting drug association
BRPI0607003A2 (pt) forma de dosagem com liberação sustentada e método para liberação sustentada de um composto de pirazina substituìda
GT200600109A (es) Derivados de acido pirimidincarboxilico y su uso
NO20091182L (no) 2-fenoksypyrimidinonanaloger
ATE510536T1 (de) Verwendung von 2,5-dihydroxybenzol-derivaten zur behandlung von reaktiven gewebeerkrankungen
WO2007070355A3 (en) Anti-inflammatory botanical products for the treatment of metabolic syndrome and diabetes
BRPI0607976A2 (pt) composição farmacêutica e uso de uma composição
EA200702534A1 (ru) Применение бензоильного производного 3-аминокарбазола для лечения расстройства, связанного с продукцией простагландина e2(pge2)
Emini Veseli Search for new therapeutic options to prevent and treat plaque neovascularization and atherogenesis

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application